Kinaxo collaborate with Onconova on Cellular profiling technology

Onconova are to collaborate with Kinaxo to use the latter’s cellular target profiling technology for development of its clinical (kinase?) drug candidates

Iressa (geftinib) shown to be effective in patients with advanced NSCLC.

Researchers from Massachusetts General Hospital have found Iressa (geftinib) shown to be effective in patients with advanced NSCLC.